Hematological disorder
Conditions
Interventions
Flash Sensor-based monitoring for 28 days
Sponsors
Kobe University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who will undergo allogeneic hematopoietic stem cell transplantation Patients who sign a written informed consent Patients who have never used FreeStyle LibrePro
Exclusion criteria
Exclusion criteria: Patients who will undergo HLA haplo-identical stem cell transplantation Patients who need to perform X-ray or CT scan more than once a week Patients who have infection on their upper arms for sensor sites Patients with contact dermatitis Patients who cannot use alcohol and chlorhexidine gluconate for sterilization Patients who have implanted medical devices Patients judged inappropriate participants for this study by their attending doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severe bleeding of the sensor site Requirement of antibiotics due to the infection of the sensor site | — |
Secondary
| Measure | Time frame |
|---|---|
| Insertion site symptoms Correlation with the value of blood glucose and interstitial fluid glucose The times of the sensor exchanges Overall survival and progression free survival at days 100 | — |
Countries
Japan
Contacts
Public ContactKimikazu Yakushijin
Kobe University Hospital Division of Medical Oncology and Hematology
Outcome results
None listed